Evaluation of NT PRO BNP Guided Therapy on Hospitalization Rate and Mortality in Patients With Chronic HF NYHA II-IY

This study is not yet open for participant recruitment.

Verified by Hillel Yaffe Medical Center, May 2007

Sponsored by:	Hillel Yaffe Medical Center
Information provided by:	Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:	NCT00469001

Purpose

To use continuous measurement of NT Pro BNP level as guide in therapy patients with CHF.

Condition	Intervention	Phase
Chronic Heart Failure	Procedure: Treatment according NT Pro BNP level	Phase I

MedlinePlus related topics: Heart Failure

Drug Information available for: Proline

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Random Sample, Prospective Study
Official Title:	Phase 1 Study of Using BNP as Guided Parameter in Treatment HF

Further study details as provided by Hillel Yaffe Medical Center:

Estimated Enrollment:	100
Study Start Date:	June 2007
Estimated Study Completion Date:	June 2009

Detailed Description:

Group of 100 patients with CHF, NYHA II-IY will be followed for 1 years in outpatient clinic of our hospital for hospitalization, death, 6 min walking protocol, number of decompensation as a primary end point. 50 patients will be treated according usual practice in outpatient clinics and in 50 patients will be additionally used level of NT Pro BNP as additional parameter.If level NT Pro BNP will be goes down will not be changes in treatment regiment. If level of NT Pro BNP will be increased treatment will be intensified.At the end of 1 year follow up we will compare the result of two strategies.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient older 18 y.old with CHF NYHA II-IY.

Exclusion Criteria:

All conditions with life expectancy less than 2 years.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00469001

Contacts

Contact: Michael Shochat, MD, PhD

972 4 6304487

Locations

Israel
Hillel Yaffe Medical Center
Hadera, Israel, 38100

Sponsors and Collaborators

Hillel Yaffe Medical Center

Investigators

Principal Investigator:

Michael Shochat, MD, PhD

Hillel Yaffe Medical Center

More Information

Study ID Numbers:	00001
Study First Received:	May 2, 2007
Last Updated:	May 2, 2007
ClinicalTrials.gov Identifier:	NCT00469001
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hillel Yaffe Medical Center:

Hospitalization and death from exacerbation CHF.

Study placed in the following topic categories:

Death
Heart Failure
Heart Diseases

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009